



ICLG

The International Comparative Legal Guide to:

Pharmaceutical Advertising 2018

15th Edition

A practical cross-border insight into pharmaceutical advertising

Published by Global Legal Group, with contributions from:

Abraham & Partneri, Attorneys-at-law
Allen & Gledhill LLP
ALRUD
A. Lopes Muniz Advogados Associados
Arnold & Porter
Arthur Cox
Astolfi e Associati Studio Legale
Baker McKenzie
BonelliErede
Clayton Utz
Clifford Chance
Cuatrecasas
Deep & Far Attorneys-at-Law
East & Concord Partners
ENSafrica
Goroditsky & Partners Ukraine
Gün + Partners
Haavind

Herbst Kinsky Rechtsanwälte GmbH
HMP LAW
Jusmedico Advokatanpartsselskab
LCH Law-Compliance Health
Liad Whatstein & Co.
Life Sciences Legal
Mannheimer Swartling Advokatbyrå
Michalopoulou & Associates lawgroup
Nishimura & Asahi
Norton Rose Fulbright Canada LLP
OLIVARES
Penkov, Markov and Partners
Pestalozzi Attorneys at Law
Quinz
Roschier, Attorneys Ltd.
Sołtysiński Kawecki & Szlęzak
Stratulat Albuлесcu Attorneys at Law
Subramaniam & Associates (SNA)



Contributing Editors

Ian Dodds-Smith & Adela Williams, Arnold & Porter

Sales Director

Florjan Osmani

Account Director

Oliver Smith

Sales Support Manager

Toni Hayward

Sub Editor

Jane Simmons

Senior Editors

Suzie Levy
Caroline Collingwood

CEO

Dror Levy

Group Consulting Editor

Alan Falach

Publisher

Rory Smith

Published by

Global Legal Group Ltd.
59 Tanner Street
London SE1 3PL, UK
Tel: +44 20 7367 0720
Fax: +44 20 7407 5255
Email: info@glgroup.co.uk
URL: www.glgroup.co.uk

GLG Cover Design

F&F Studio Design

GLG Cover Image Source

iStockphoto

Printed by

Stephens & George
Print Group
June 2018

Copyright © 2018
Global Legal Group Ltd.
All rights reserved
No photocopying

ISBN 978-1-912509-16-4
ISSN 1743-3363



General Chapter:

1	Providing Information to Patients in the EU: Where Are We Now? – Jackie Mulryne & Fenella Fletcher-Flood, Arnold & Porter	1
---	--	---

Country Question and Answer Chapters:

2	Australia	Clayton Utz: Colin Loveday & Greg Williams	7
3	Austria	Herbst Kinsky Rechtsanwälte GmbH: Dr. Sonja Hebenstreit & Dr. Isabel Funk-Leisch	21
4	Belgium	Quinz: Olivier Van Obberghen & Nele Jonckers	34
5	Brazil	A. Lopes Muniz Advogados Associados: Marcos Lobo de Freitas Levy & Mariana C. Lopes Muniz	45
6	Bulgaria	Penkov, Markov and Partners: Roman Stoyanov & Yura Mincheva	54
7	Canada	Norton Rose Fulbright Canada LLP: Sara Zborovski & Ian Trimble	66
8	China	East & Concord Partners: Charles Feng	76
9	Czech Republic	Abraham & Partneri, Attorneys-at-law: Martin Abraham & Arne Feber	84
10	Denmark	Jusmedico Advokatanpartsselskab: Jan Bjerrum Bach & Martin Binzer Lind	92
11	England & Wales	Arnold & Porter: Silvia Valverde & Adela Williams	109
12	Finland	Roschier, Attorneys Ltd.: Mikael Segercrantz & Johanna Lilja	124
13	France	LCH Law-Compliance Health: Laure Le Calvé & Johanna Benichou	136
14	Germany	Clifford Chance: Dr. Peter Dieners & Carolin Kemmner	146
15	Greece	Michalopoulou & Associates lawgroup: Ioanna Michalopoulou & Ioli Chatziantoniou	161
16	India	Subramaniam & Associates (SNA): Aditi Subramaniam & Sanuj Das	171
17	Ireland	Arthur Cox: Colin Kavanagh & Ciara Farrell	182
18	Israel	Liad Whatstein & Co.: Liad Whatstein & Uri Fruchtman	195
19	Italy	Astolfi e Associati Studio Legale: Sonia Selletti	206
20	Japan	Nishimura & Asahi: Somuku Iimura & Yoko Kasai	217
21	Korea	HMP LAW: Hye Yeon Lim & Jong Bae Shin	228
22	Mexico	OLIVARES: José Alejandro Luna Fandiño & Armando Arenas Reyes	237
23	Netherlands	Life Sciences Legal: Anke Heezius	249
24	Norway	Haavind: Håkon Austdal & Vebjørn Krag Iversen	257
25	Poland	Sołtysiński Kawecki & Szlęzak: Dr. Ewa Skrzydło-Tefelska & Joanna Ryzek	267
26	Portugal	Cuatrecasas: Joana Silveira Botelho	276
27	Romania	Stratulat Albulescu Attorneys at Law: Ana Kusak	285
28	Russia	ALRUD: Anton Dzhuplin & Maria Ostashenko	295
29	Singapore	Allen & Gledhill LLP: Dr. Stanley Lai, SC & Gloria Goh	304
30	South Africa	ENSafrica: Altair Richards & Amrisha Raniga	314

Continued Overleaf →

Further copies of this book and others in the series can be ordered from the publisher. Please call +44 20 7367 0720

Disclaimer

This publication is for general information purposes only. It does not purport to provide comprehensive full legal or other advice. Global Legal Group Ltd. and the contributors accept no responsibility for losses that may arise from reliance upon information contained in this publication. This publication is intended to give an indication of legal issues upon which you may need advice. Full legal advice should be taken from a qualified professional when dealing with specific situations.



Country Question and Answer Chapters:

31	Spain	Baker McKenzie: Cecilia Pastor & Ester Navas	329
32	Sweden	Mannheimer Swartling Advokatbyrå: Helén Waxberg & Camilla Nortoft	342
33	Switzerland	Pestalozzi Attorneys at Law: Dr. Lorenza Ferrari Hofer	353
34	Taiwan	Deep & Far Attorneys-at-Law: Yu-Li Tsai & Lu-Fa Tsai	363
35	Turkey	Gün + Partners: Özge Atılgan Karakulak & Dicle Doğan	372
36	Ukraine	Gorodisky & Partners Ukraine: Nina Moshynska & Maksym Bocharov	384
37	United Arab Emirates	BonelliErede: Andrea Carta Mantiglia & Helen Roberts	393
38	USA	Arnold & Porter: Daniel A. Kracov & Mahnu V. Davar	405

Finland

Roschier, Attorneys Ltd.

Mikael Segercrantz



Johanna Lilja



1 General – Medicinal Products

1.1 What laws and codes of practice govern the advertising of medicinal products in your jurisdiction?

Advertising of medicinal products in Finland is governed by the Medicines Act (395/1987, as amended) and the Medicines Decree (693/1987, as amended).

Also, the Code of Ethics (revised 1 January 2017) (“PIF Code”) issued by Pharma Industry Finland (“PIF”) contains detailed provisions on the marketing of medicinal products, complementing the statutory legislation. The PIF Code has been drafted and implemented by the representatives of the pharmaceutical industry. All members of PIF (which includes, in practice, most of the major players in the pharmaceutical industry in Finland) have undertaken to comply with the PIF Code and therefore it represents the generally accepted code of conduct of the industry.

On a general level, the Consumer Protection Act (38/1978, as amended), which is applicable to consumer marketing, and the Act on Unfair Business Practices (1061/1978, as amended), which is applicable to business-to-business marketing, may apply to the advertising of medicinal products. With the exceptions of an action based on unfair business practices (see question 1.9 below) and comparative advertising (see question 3.4 below), these general provisions will not be described in more detail below.

1.2 How is “advertising” defined?

Marketing of medicinal products is defined as all types of publicity, marketing and promotional activities intended to promote the prescription, supply, purchase or use of medicinal products. This includes, *inter alia*, advertising directed at the general public, advertising directed at persons qualified to prescribe or supply medicinal products, sales promotion and activities of medicinal sales representatives. Also, distribution of samples shall be considered as marketing of medicinal products.

1.3 What arrangements are companies required to have in place to ensure compliance with the various laws and codes of practice on advertising, such as “sign off” of promotional copy requirements?

Pharmaceutical companies must have a scientific service unit

responsible for the information distributed on the medicinal products of the company and for the correctness of such information. Under the PIF Code, the scientific service unit must employ at least one physician or pharmacist responsible for the approval of the company’s marketing measures before their publication, including events, advertisement gifts and market studies. This person must ensure that the final form of the marketing measure complies with the PIF Code and the legislation on pharmaceuticals marketing.

1.4 Are there any legal or code requirements for companies to have specific standard operating procedures (SOPs) governing advertising activities or to employ personnel with a specific role? If so, what aspects should those SOPs cover and what are the requirements regarding specific personnel?

No, there are no legal or code requirements for companies to have specific standard operating procedures, although most companies have such in place. In terms of specific personnel, see question 1.3 above for requirements concerning scientific service units.

1.5 Must advertising be approved in advance by a regulatory or industry authority before use? If so, what is the procedure for approval? Even if there is no requirement for prior approval in all cases, can the authorities require this in some circumstances?

There is no mandatory requirement for prior approval of advertisements by the Finnish Medicines Agency (“FIMEA”) or the PIF. However, a pharmaceutical company may voluntarily request the supervisory body acting under the PIF to inspect an advertisement directed at consumers in advance. Notwithstanding the aforementioned, it is stipulated in the PIF Code that all television and radio advertisements for medicinal products shall be submitted for preliminary inspection to the PIF.

The supervisory body operating under the PIF may, in connection with the preliminary inspection, approve the contemplated radio or television advertisement as such, or with amendments, or reject it.

If material other than the final advertisement is presented, the statement of the supervisory body given in connection with the examination of such unfinished material will not be considered as the supervisory body’s final opinion of the finished advertisement. The supervisory body is, however, bound to the opinion given by it on the compliance of the manuscript with the PIF Code. The supervisory body must give the applicant a separate justified decision on the

preliminary inspection of the advertisement, indicating the date of the decision. The decision shall be notified to the applicant immediately.

A preliminary advertisement which has been inspected can be shown for a period not exceeding three years from the date of approval.

Concerning marketing measures other than radio or television advertisements, the preliminary inspection may focus on the question of whether the measure in question complies with the PIF Code and whether it would be prohibited through subsequent supervision. The preliminary inspection decision must specify the reasons for which the marketing measure does not comply with the PIF Code.

1.6 If the authorities consider that an advertisement which has been issued is in breach of the law and/or code of practice, do they have powers to stop the further publication of that advertisement? Can they insist on the issue of a corrective statement? Are there any rights of appeal?

FIMEA may prohibit a company to continue or repeat marketing that violates the provisions of the Medicines Act and Medicines Decree. FIMEA may also order a company to rectify improper marketing, if considered appropriate due to the safety risk of medicinal products. A conditional fine may support a prohibition or order issued by FIMEA.

The decision of FIMEA to prohibit or rectify improper marketing may be appealed to an Administrative Court and further to the Supreme Administrative Court. The time to appeal is 30 days from the date of service of the decision. The decision of FIMEA must be complied with unless the appellate court rules otherwise.

1.7 What are the penalties for failing to comply with the rules governing the advertising of medicines? Who has responsibility for enforcement and how strictly are the rules enforced? Are there any important examples where action has been taken against pharmaceutical companies? If there have not been such cases please confirm. To what extent may competitors take direct action through the courts in relation to advertising infringements?

A person that intentionally, or due to negligence, acts in violation of the Medicines Act or Medicines Decree or FIMEA's prohibition or order may be sentenced for a pharmaceutical offence to fines or imprisonment of up to one year. If the act is only due to negligence, the person may be fined for a pharmaceutical infringement. Criminal proceedings are handled by the general courts and initiated by the general prosecutor.

In October 2006, FIMEA prohibited a major pharmaceutical company from marketing a medicinal product with material which was not in accordance with the approved summary of product characteristics. FIMEA also prohibited such marketing which omits an essential detail for the medical value of the medicinal product or which refers to a clinical trial in a way that misrepresents the conclusions, extent and significance of the trial. The prohibitions were supported with a conditional fine in the amount of EUR 2 million.

It is not common for competitors to take direct action through courts for advertisement infringements but it happens from time to time that a pharmaceutical company files a complaint with FIMEA

against a competitor (which is not a member of PIF) and requests that it takes action and prohibits the marketing of the competitor.

1.8 What is the relationship between any self-regulatory process and the supervisory and enforcement function of the competent authorities? Can and, in practice, do, the competent authorities investigate matters drawn to their attention that may constitute a breach of both the law and any relevant code and are already being assessed by any self-regulatory body? Do the authorities take up matters based on an adverse finding of any self-regulatory body?

The supervisory bodies acting under the PIF monitor the appropriateness of marketing of medicinal products by PIF's member companies and compliance with the PIF Code. A matter may become pending in the supervisory bodies on the bodies' own initiative or based on a complaint. Anyone can lodge a complaint against measures taken by PIF's companies committed to the PIF Code falling within the scope of application of the PIF Code. The sanctions which the supervisory bodies of the PIF may issue for violation against the PIF Code include: an admonition for future reference; a request to abstain from incorrect activity; a processing charge; a compensation payment; a sanction payment (minimum EUR 1,000 and maximum EUR 100,000); and an order to rectify and correct the measures taken. In addition, a company may be ordered to pay liquidated damages (minimum EUR 20,000 and maximum EUR 300,000). The supervisory body may also submit the matter to FIMEA for action if e.g. a company continues its non-complying activity in spite of an admonition, request to abstain from incorrect marketing or temporary request to abstain.

Disagreements between pharmaceutical companies concerning a violation of the PIF Code shall be submitted for examination to the system set forth in the PIF Code before they may be brought to the attention of the relevant authorities. A member company that has bypassed said system can be ordered to pay liquidated damages. Liquidated damages can also be imposed if the company violates a contract made amicably with another pharmaceutical company in relation to the discontinuation of incorrect marketing.

If a case is being examined by the authorities, the supervisory body of the PIF does not issue a decision on it until such proceedings have been finalised. After a final decision by the authorities has been issued, the case can be decided by the supervisory body, considering the dimensions of the decision by the authorities as well as the eventual sanctions imposed. If the examination of the case by the authorities is considerably delayed, the supervisory body of the PIF can, exceptionally, take up the case despite the pending process with the authorities.

FIMEA may handle a matter even though it is being assessed or has been decided by the supervisory body of the PIF.

According to the PIF Code, the Inspection Board or the Supervisory Commission can, upon the request of the interested party, at their discretion, impose an EUR 5,000 compensation payment for an unfounded complaint made merely for the purpose of harming the competitor, payable to the company suffering from the complaint to cover the costs incurred for the reply to the unfounded complaint.

1.9 In addition to any action based specifically upon the rules relating to advertising, what actions, if any, can be taken on the basis of unfair competition? Who may bring such an action?

Under the Act of Unfair Business Practices, practices that are contrary to good business practices or that are otherwise unfair in relation to other entrepreneurs may not be used in marketing. Marketing shall also clearly indicate its commercial purpose and the party or the benefit of whom the marketing is carried out. Furthermore, it is prohibited to use in commercial activities such false or misleading expressions regarding their own or another entrepreneur's business activities that are likely to affect the demand or supply of goods or to harm another entrepreneur's business activities.

An action based upon the violation of the provisions of the Act on Unfair Business Practices may be initiated at the Market Court by an entrepreneur who is affected by the violating action or whose activity it may damage, e.g. a competitor. The Market Court may prohibit the continuation of the unfair practice and order suitable rectifying measures. The Market Court may also support a prohibition or rectifying measure order with a conditional fine. Finally, the losing party may be required to reimburse the opposing party's legal costs. A party may appeal a decision by the Market Court to the Supreme Court if the Supreme Court grants leave to appeal.

A competitor that has suffered damages due to the unfair practice of another entrepreneur may also sue for damages at a General Court. Finally, the public prosecutor may bring criminal charges against an entrepreneur that has deliberately, or out of gross negligence, used false or misleading expressions in marketing.

2 Providing Information Prior to Authorisation of Medicinal Product

2.1 To what extent is it possible to make information available to healthcare professionals about a medicine before that product is authorised? For example, may information on such medicines be discussed, or made available, at scientific meetings? Does it make a difference if the meeting is sponsored by the company responsible for the product? Is the position the same with regard to the provision of off-label information (i.e. information relating to indications and/or other product variants not authorised)?

Only medicinal products referred to in the Medicines Act may be advertised or marketed as medicinal products. It is prohibited to market medicinal products lacking market authorisation in Finland.

It is not acceptable e.g. at training events, to give specific information of non-authorised medicinal products using the contemplated trade name. However, it is acceptable to give objective information of published research results regarding non-authorised medicinal products, by using the generic name.

In case a healthcare professional has obtained information, e.g. at an international training event, of the name of a medicinal product which has not yet been authorised in Finland but will be marketed using the same name, it is acceptable upon request to inform the doctor thereof. The active marketing of such product is prohibited.

The aforementioned prohibition to market medicinal products which do not have a marketing authorisation in Finland applies also at international events arranged in Finland, according to Finnish legislation.

However, general information on a pharmaceutical company and their portfolio as well as research activities and results is not considered advertising (in the meaning of Finnish law on medicines) and thus is allowed. In practice, this leaves two possibilities to distribute information about non-authorised products:

- 1) marketing of the company itself, where the product portfolio can also mention products without marketing authorisation in Finland; and
- 2) information of a company's product development programmes, without any brand names, but information of the results of research programmes. No therapeutic claims are allowed.

2.2 May information on unauthorised medicines and/or off-label information be published? If so, in what circumstances?

It is acceptable to provide neutral information of scientific research results concerning unauthorised products and/or off-label information. However, the trade name of products shall not be used.

2.3 Is it possible for companies to issue press releases about unauthorised medicines and/or off-label information? If so, what limitations apply? If differences apply depending on the target audience (e.g. specialised medical or scientific media vs. main stream public media) please specify.

The same rules apply as in question 2.2 above. However, in case the press release is issued by a listed company and based on the statutory information liability of the pharmaceutical companies, such press release could in certain situations contain also the trade name of the product, as this type of press release is outside the scope of the PIF Code.

When issuing a press release about unauthorised medicines and/or off-label information, the issuer must ensure that such press release does not contain any elements of marketing whatsoever. The same limitation applies to specialised/scientific media (see above answer to question 2.1).

2.4 May such information be sent to healthcare professionals by the company? If so, must the healthcare professional request the information?

It is acceptable to provide information of scientific research results for medicinal products which are not yet authorised, only if the healthcare professional has explicitly requested the information; unsolicited distribution of information is, as the main rule, not allowed. Information sent to healthcare professionals upon request may not contain any trade names of unauthorised products and reference shall only be made to the name of the active ingredient. Furthermore, information on the research results shall be presented in a neutral and objective way.

2.5 How has the ECJ judgment in the *Ludwigs* case, Case C-143/06, permitting manufacturers of non-approved medicinal products (i.e. products without a marketing authorisation) to make available to pharmacists price lists for such products (for named-patient/compassionate use purposes pursuant to Article 5 of the Directive), without this being treated as illegal advertising, been reflected in the legislation or practical guidance in your jurisdiction?

According to the Medicines Decree, product and price lists are not considered marketing. However, such product and price lists may not contain any claims concerning the medicinal product in question. This rule also applies to products approved by FIMEA for named-patient/compassionate use purposes.

2.6 May information on unauthorised medicines or indications be sent to institutions to enable them to plan ahead in their budgets for products to be authorised in the future?

According to FIMEA, the offering of a pharmaceutical product without valid marketing authorisation (or with a pending marketing authorisation) in tender offers is prohibited by virtue of the Medicines Act, unless the tender offer has not been specified to explicitly concern said product.

2.7 Is it possible for companies to involve healthcare professionals in market research exercises concerning possible launch materials for medicinal products or indications as yet unauthorised? If so, what limitations apply? Has any guideline been issued on market research of medicinal products?

It is possible to enter into consultancy agreements with healthcare professionals, e.g. for market research purposes. It should be noted, however, that such consultancy relationships must fulfil certain criteria set forth in the PIF Code (e.g. a written agreement requirement and that the consultancy fees are on a reasonable level) and that the pharmaceutical company may not engage more healthcare professionals, e.g. in market research, than is reasonably needed.

3 Advertisements to Healthcare Professionals

3.1 What information must appear in advertisements directed to healthcare professionals?

Advertising of medicinal products to persons qualified to prescribe or supply such products shall include essential information on the medicinal product and its use. In particular, such advertising shall include:

- essential information, in accordance with the summary of product characteristics, on the purpose of use, recommended use, effect and safety of the product;
- legal conditions of supply;
- conditions of reimbursement under the health insurance system, average treatment costs, where possible, and retail prices of different packages; and
- the date when the advertisement was prepared or revised.

All information given in marketing should correspond to the approved summary of product characteristics, be accurate, up-to-date, verifiable and clear enough to enable the reader to form an opinion of the therapeutic value of the product. Quotations, as well as tables and other illustrative matter taken from medicinal journals or scientific research shall be faithfully reproduced and the precise sources indicated.

3.2 Are there any restrictions on the information that may appear in an advertisement? May an advertisement refer to studies not mentioned in the SmPC?

As the main rule, an advertisement may not contain any information that is not compliant to its content with the approved SmPC (e.g. off-label information).

However, an advertisement may refer to studies which have not been explicitly mentioned in the SmPC, provided that such studies have been appropriately published, the information is compliant with the SmPC and the reference fulfils other general requirements for advertisements as listed above in question 3.1 and below in question 3.4. Moreover, it is permissible to include the mention of these in the material for the marketing of medicinal products articles which have been accepted for publication in scientific journals, as well as the results of trials or studies submitted to the regulatory authorities in association with marketing authorisation applications. The unpublished study results must meet the same quality criteria applied to published results. Any reference to study results must be associated with explicit information on the trial arrangements (e.g. *in vivo*, *in vitro*, animal testing).

As an exception to the above, reference may also be made to such study results which have not been published, if they can be deemed to have material significance for the medication of patients. New information has material significance if it refers to a serious disease and if there is clear proof that the treatment in question is superior to the earlier treatments.

3.3 Are there any restrictions to the inclusion of endorsements by healthcare professionals in promotional materials?

The PIF Code sets forth that pharmaceutical marketing must not contain direct and active recommendations to use the medicine given by scientists, healthcare professionals or celebrities.

3.4 Is it a requirement that there be data from any, or a particular number of, "head to head" clinical trials before comparative claims may be made?

There are no numeral requirements to this extent. The PIF Code only stipulates that comparison between different active ingredients shall be based on scientific evidence.

Furthermore, any research results included in the material for the marketing of medicinal products must have been published in article form in a scientific journal. Moreover, it is permissible to include this in the material for the marketing of medicinal products articles which have been accepted for publication in a scientific journal, as well as trials supplied to the regulatory authorities in association with a marketing authorisation application.

The use of unpublished material, such as abstracts or posters of similar materials which have not been published in scientific journals, is, as a rule, prohibited.

3.5 What rules govern comparative advertisements? Is it possible to use another company's brand name as part of that comparison? Would it be possible to refer to a competitor's product or indication which had not yet been authorised in your jurisdiction?

The Medicines Act stipulates that marketing may not provide a misleading or exaggerated picture of the formula, origin or pharmaceutical significance of a product, or be inappropriate in any other similar way.

In addition, the Unfair Business Practices Act contains general provisions regarding comparative advertising which may be applicable to the marketing of medicinal products.

Furthermore, the PIF Code stipulates that comparisons between different medicinal products, active ingredients, excipients or other characteristics must be accurate and reliable. The graphic comparison and price comparison of the product shall be clearly justifiable. The object in comparison shall be clearly recognisable.

The packages and dosages used in price comparisons shall correspond to each other. When the prices of products are compared, the medicinal products covered by the comparison and their trade names shall be clearly indicated. When using comparison in marketing, the time of comparison or the date of publication shall be disclosed.

Special weight shall be given in the comparison to the objectivity of marketing and the correctness of information.

There are no explicit rules prohibiting a company from referring to a competitor's product or indication which has not yet been authorised in Finland. However, such information may be considered inessential from the point of view of a Finnish consumer and healthcare professional as the product is not available for sale or prescription in Finland. Consequently, it is possible that comparative advertising of this kind may be considered inappropriate.

3.6 What rules govern the distribution of scientific papers and/or proceedings of congresses to healthcare professionals?

Scientific material published by the pharmaceutical industry, e.g. scientific papers and proceedings of congresses, are explicitly excluded from the scope of the marketing provisions of the Medicines Act and Decree, as well as the PIF Code. There are no specific rules on the distribution of scientific material. Distribution of scientific materials is basically permitted as long as it constitutes a genuine exchange of scientific information and is not a hidden sales promotion of a medicinal product.

3.7 Are "teaser" advertisements (i.e. advertisements that alert a reader to the fact that information on something new will follow, without specifying the nature of what will follow) permitted?

There are no specific rules on "teaser" advertisements, and basically all advertising directed to healthcare personnel shall fulfil the content requirements described above (see question 3.1). An exception to this basic rule involves "reminder advertising". Reminder advertising means advertising that is intended solely as a reminder of the name of the product. Reminder advertising may contain only the trade name of the product, the name of its active substance and the trademark of the product, as well as the holder of the marketing authorisation, marketer, importer or manufacturer and its company

logo. The nature of a reminder advertisement is thus the opposite from that of a teaser advertisement, in the sense that reminder advertisements are used after a product has already become known to remind the target group of the existence of the product. It remains unclear, however, whether the provisions on reminder advertisements could also be a basis for permitting teaser advertisements.

4 Gifts and Financial Incentives

4.1 Is it possible to provide healthcare professionals with samples of medicinal products? If so, what restrictions apply?

Samples of medicinal products may be distributed only to persons entitled to prescribe and supply them. Samples of prescription drugs can be distributed only to persons entitled to prescribe medicinal products. If the prescription is subject to restriction of supply, the sample can only be given to the doctor entitled to prescribe it. During the two years following the introduction of the medicinal product to the market or the adoption of its reimbursable price, one package of each medicinal product, strength and pharmaceutical form can be given as a free sample to each recipient in one calendar year. The free medicine samples can be distributed for a maximum of two years. However, this does not apply to distribution of free samples of self-care medicinal products.

A sample may be distributed only on the basis of a written, signed and dated request, and pharmaceutical companies must keep records of the free samples given in each calendar year. A sample shall be exactly the same as the smallest package size available on the market. Each sample shall be accompanied by a summary of product characteristics.

Narcotics, including psychotropic substances and substances that mainly affect the central nervous system, must not be distributed as samples.

4.2 Is it possible to give gifts or donations of money to healthcare professionals? If so, what restrictions apply? If monetary limits apply, please specify.

Under the Medicines Act, sales promotion of medicinal products to healthcare professionals, such as gifts and benefits, must be inexpensive and related to their professional activities. Hospitality at sales promotion events must be reasonable and secondary compared to the purpose of the event.

The PIF Code contains stricter rules on incentives, gifts, advertising gifts and other support measures. Under the Code, it is forbidden to give promotional gifts related to prescription-only medicines. While the distribution of promotional gifts related to the marketing of non-prescription medicines must be reasonable, such gifts must have minor economic significance for the recipient and they must have bearing on their professional operations. Such gifts may not exceed EUR 35 (retail price including VAT). Healthcare professionals must not be offered or otherwise provided with direct or disguised economic incentives, gifts or promotional articles constituting inducements. Making donations or awarding grants to individual healthcare professionals is only permitted for performing so-called investigator-initiated clinical trials with a proper study protocol, which is approved by the regulatory authority and ethics committee and otherwise meets the statutory criteria for clinical trials.

It should also be noted that offering an additional benefit may be considered a bribe if the benefit is significant and may induce the recipient to make such acquisitions that would not otherwise be justifiable for the institution.

4.3 Is it possible to give gifts or donations of money to healthcare organisations such as hospitals? Is it possible to donate equipment, or to fund the cost of medical or technical services (such as the cost of a nurse, or the cost of laboratory analyses)? If so, what restrictions would apply? If monetary limits apply, please specify.

Donations to institutions as such are possible. The PIF Code stipulates that donations, grants and benefits offered to institutions, organisations or associations are permitted if their members are healthcare professionals or if they provide healthcare services or engage in research and their purpose is to support healthcare and research. Such donations or grants must not constitute an incentive for, *inter alia*, the recommendation, prescription, purchase or supply of a particular medicinal product. No monetary limits apply for such donations.

Under the PIF Code, a company can engage in sponsorship activity using the company name. However, the use of a product name is not allowed. The PIF Code also contains specific rules on the obligation to disclose economic benefits targeted at healthcare organisations or professionals. The requirements on disclosure of transfers of value set forth in the PIF Code are in line with the requirements of the EFPIA Disclosure Code.

4.4 Is it possible to provide medical or educational goods and services to healthcare professionals that could lead to changes in prescribing patterns? For example, would there be any objection to the provision of such goods or services if they could lead either to the expansion of the market for, or an increased market share for, the products of the provider of the goods or services?

Sales promotion may not be inappropriate or such that it may endanger the trust of the general public that the prescription, use or assignment of medicinal products is independent. Consequently, arrangements where medical or educational goods and services are provided to doctors that could lead to changes in prescribing patterns will most likely be considered inappropriate.

The PIF Code further stipulates that healthcare professionals can be provided with informative and educational material and medicinal supplies under certain conditions if these do not constitute an incentive for, *inter alia*, the recommendation, prescription or sale of a particular medicinal product.

4.5 Do the rules on advertising and inducements permit the offer of a volume-related discount to institutions purchasing medicinal products? If so, what types of arrangements are permitted?

Pharmaceutical companies are not permitted to grant discounts to individual pharmacies, and the wholesale price shall be the same to all pharmacies. The wholesale price shall include all rebates, refunds and other benefits that are granted to a pharmacy. The aforementioned restrictions do not apply to such medicinal products

which may be sold in places other than pharmacies, such as nicotine replacements. It is, however, permitted for pharmaceutical companies to grant discounts to welfare and health units, e.g. hospital districts and individual hospital pharmacies.

4.6 Is it possible to offer to provide, or to pay for, additional medical or technical services or equipment where this is contingent on the purchase of medicinal products? If so, what conditions would need to be observed? Are commercial arrangements whereby the purchase of a particular medicine is linked to provision of certain associated benefits (such as apparatus for administration or the provision of training on its use) as part of the purchase price (“package deals”) acceptable?

There are no explicit rules prohibiting the provision of equipment or services to third-party institutions contingent on the purchase of medicinal products. However, it cannot be ruled out that in some circumstances, such an arrangement may be considered unacceptable, particularly where the arrangement jeopardises the public’s trust in the impartiality of prescribing or supplying medicinal products.

Commercial arrangements whereby the purchase of a particular medicine is linked to provision of certain associated benefits as a part of the purchase price are not acceptable as the provision of certain associated benefits (such as administrators) may not constitute an incentive for the purchase of a medicinal product.

As for consumers, it is, as a main rule, forbidden to give the buyer of a non-prescription medicine another product or benefit (giveaways) at the same price.

4.7 Is it possible to offer a refund scheme if the product does not work? If so, what conditions would need to be observed? Does it make a difference whether the product is a prescription-only medicine, or an over-the-counter medicine?

The Medicines Act and Medicines Decree do not contain any specific provisions to this extent. According to the PIF Code, the marketing of medicinal products shall follow good practices in order to inspire truth and esteem. It is possible, however, that a refund scheme may be considered contrary to good marketing practice.

Furthermore, it is prohibited in consumer marketing to suggest that the effects of the product are guaranteed, or that its use is not associated with any adverse effects, or suggest without grounds to prove it that the effects are equally good or better than those of another treatment or medication.

The nature of the product, whether it is a prescription-only or an over-the-counter product, does not make any difference.

4.8 May pharmaceutical companies sponsor continuing medical education? If so, what rules apply?

Pharmaceutical companies may sponsor further or complementary training. However, according to the Finnish Medicinal Association, events organised by pharmaceutical companies themselves do not fulfil the requirements for post-graduate or further professional education (i.e. no CME accreditation). When a pharmaceutical company sponsors a scientific event, the attendees and invitees must

be clearly informed of this. Furthermore, pharmaceutical companies may participate in the expenses of further complementary training only if the company is provided with a possibility to actively distribute information of their products in the training event.

According to the Guidelines concerning Continuing Medical Education (2007) published by the Finnish Medicinal Association, it is further recommended that physicians and other healthcare professionals participating, e.g. as lecturers in continuing medical education events sponsored by pharmaceutical companies, disclose their financial and other interests (e.g. grants and awards received from the pharmaceutical industry, shareholding in pharma companies, etc.). The conflict of interest disclosure should be made in the programme of the event.

4.9 What general anti-bribery rules apply to the interactions between pharmaceutical companies and healthcare professionals or healthcare organisations? Please summarise. What is the relationship between the competent authorities for pharmaceutical advertising and the anti-bribery/anti-corruption supervisory and enforcement functions? Can and, in practice, do the anti-bribery competent authorities investigate matters that may constitute both a breach of the advertising rules and the anti-bribery legislation, in circumstances where these are already being assessed by the pharmaceutical competent authorities or the self-regulatory bodies?

The Finnish Criminal Code (39/1889) contains the general anti-bribery rules regarding the giving and accepting of a bribe. The Criminal Code contains provisions on active bribery of a public official or a Member of Parliament, passive bribery of a public official or a Member of Parliament, active bribery in business and passive bribery in business. The Criminal Code also contains provisions on aggravated forms of the mentioned crimes. The provisions of the Criminal Code apply to the interaction between pharmaceutical companies and healthcare professionals or organisations if the interaction meets the essential elements of the offence set forth in the Criminal Code.

Finland does not have a special authority focusing particularly on investigating bribery-related offences. As it is the case with other offences, the police force is responsible for investigating bribery-related offences. In cases of a more complex nature, i.e. involving organised crime, international connections or involvement of senior public officials, the investigations are normally conducted by the National Bureau of Investigation. After the investigation has been completed the case is turned to the prosecutorial service for consideration of charges. FIMEA monitors that the medicinal products are advertised according to the Medicines Act and Decree. Also the PIF monitors the appropriateness of the marketing of medicinal products by PIF's member companies and compliance with the PIF Code.

The police force shall conduct an investigation when, on the basis of a report made to it or otherwise, there is a reason to suspect that a crime has been committed. Thus, the police force may start an investigation even though the matter is already subject to assessment by FIMEA or PIF. See question 1.8 on the relationship regarding the processes instituted by PIF and competent authorities.

5 Hospitality and Related Payments

5.1 What rules govern the offering of hospitality to healthcare professionals? Does it make a difference if the hospitality offered to those healthcare professionals will take place in another country and, in those circumstances, should the arrangements be approved by the company affiliate in the country where the healthcare professionals reside or the affiliate where the hospitality takes place? Is there a threshold applicable to the costs of hospitality or meals provided to a healthcare professional?

According to the PIF Code, events organised or sponsored by the pharmaceutical industry shall observe the customary local norms of hospitality. The hospitality must be reasonable and suitable to the situation, as well as secondary to the purpose of the event. Furthermore, hospitality must not exceed what typical participants in the event would be prepared to pay if they had to cover their own expenses. Hospitality shall reinforce the positive public image of the pharmaceutical industry and may not endanger the public trust towards neutrality of medicine subscription and supply. The overall daily expenditure on meals (food and beverages) per participant must not exceed EUR 45 for lunch and EUR 100 for dinner.

Scientific or training events may take place abroad provided they have sufficient scientific- or training-related justification. The PIF Code of Ethics must also be followed in pharmaceutical marketing and other operations falling within the scope of application of the Code, targeted at Finns abroad or in international congresses. In addition, local instructions and requirements should be adhered to. Please also see question 5.2 below.

5.2 Is it possible to pay for a healthcare professional in connection with attending a scientific meeting? If so, what may be paid for? Is it possible to pay for his expenses (travel, accommodation, enrolment fees)? Is it possible to pay him for his time?

According to the PIF Code, the pharmaceutical industry may participate in the costs of updating or advanced healthcare training, provided the industry is given the possibility to participate in the information activity. The main focus of the event shall be medical information, or it will relate to medical research. The majority of the participant's time shall be consumed in scientific programmes or training. The costs shall essentially relate to scientific programmes and information, and be allocated only to professionals who receive the information.

The event shall take place at a location which is suitable, taking into account the scientific or training programme of the event. The event may not be organised in a "luxury" location or at a resort known for its spare time and entertainment activities. The event may also take place abroad provided it has sufficient scientific or training-related justification.

The cost may only include registration, travel, accommodation and meal expenses of the scientific or training event. It is not allowed to pay for the attendee's time.

The event and travel time must be organised so that, excluding travel days, the majority of the participant's time will be spent on scientific programmes and training.

5.3 To what extent will a pharmaceutical company be held responsible by the regulatory authorities for the contents of, and the hospitality arrangements for, scientific meetings, either meetings directly sponsored or organised by the company or independent meetings in respect of which a pharmaceutical company may provide sponsorship to individual healthcare professionals to attend?

The hospitality arrangements for scientific meetings are most likely considered marketing within the meaning of the Medicines Act and Decree, and the issues highlighted in questions 5.1 and 5.2 above must be followed in such hospitality arrangements.

FIMEA may prohibit a company to continue or repeat hospitality arrangements that violate the provisions of the Medicines Act and Decree. A conditional fine may support a prohibition or order issued by FIMEA (see question 1.6).

5.4 Is it possible to pay healthcare professionals to provide expert services (e.g. participating in advisory boards)? If so, what restrictions apply?

Basically, yes. However, the payment should be reasonable and should strictly relate to professional activities, otherwise there is a risk that such payment will be considered as an inappropriate gift. In their cooperation with doctors, companies must ensure that the agreement relating to the compensation is not used to circumvent the rules and regulations on the promotion of medicinal products.

The use of healthcare professionals as a group or as individual consultants or advisers must be arranged to meet certain criteria defined in the PIF Code (e.g. a written contract is required, consultants are liable to disclose their relationship to the company whenever writing or speaking publicly about the subject matter of the consultation relationship).

5.5 Is it possible to pay healthcare professionals to take part in post-marketing surveillance studies? What rules govern such studies?

It is not prohibited for doctors to take part in post-marketing surveillance. (See also question 5.3.) According to the PIF Code, in organising market research, special attention must be paid to the protection of the privacy of the patients, as well as to the voluntary participation in such research. In addition, market research must not have an impact on the treatment of individual patients and should be based on objectiveness, and the compensation paid for the implementation of the research must be of reasonable economic value. Market research must also be limited in scope and the opinion of healthcare professionals must not be asked repeatedly. Market research may not contain any elements of marketing and the research may only be done on medicinal products with valid marketing authorisations.

5.6 Is it possible to pay healthcare professionals to take part in market research involving promotional materials?

See questions 2.7, 5.4 and 5.5 above. With regard to market research, it is permissible to compensate healthcare professionals

for their participation, but according to the PIF Code the amount of the remuneration shall be minor. PIF has considered EUR 35 to be an acceptable compensation, but if it is a case of extensive research which takes more time, the acceptable level of remuneration may even be EUR 100.

6 Advertising to the General Public

6.1 Is it possible to advertise non-prescription medicines to the general public? If so, what restrictions apply?

The marketing of medicines shall encourage the appropriate use of the medicines, and information given in marketing must correspond to the summary of product characteristics. Marketing may not solicit the general public to an unnecessary use of medicines, provide a misleading or exaggerated picture of the formula, origin or significance as a medicine, or otherwise be inappropriate. Products may be marketed as medicines only if defined as such pursuant to the Medicines Act.

Advertisements to the general public shall include the product name and the name of the active ingredient, if the product contains only one active ingredient, as well as information necessary for the correct and safe use and an explicit and easily readable request to read separate instructions. According to the PIF Code, the advertisement must also include the indication and the name of the holder of the marketing authorisation, importer or marketer.

In advertisements to the general public, it is prohibited to include groundless statements regarding health or direct advertising at children or give an exaggerated or misleading picture of the effects of a medicinal product.

Advertisements to the general public must not refer to clinical trials in such a way that a false picture is given of the conclusion, extent or significance of the trials. According to the Medicines Decree, advertisements to the general public shall be set out in such a way that it is evident that the message is an advertisement of medicinal products and must not include any information that:

- gives the impression that it is unnecessary to consult a doctor or that a treatment recommended by a doctor is not necessary;
- suggests that the effects of the product are guaranteed, or that its use is not associated with any adverse reactions, or suggests that the effects are equally good or better than those of another treatment or medication;
- suggests that the health of the subject can be enhanced by taking the medicine or that the health of the subject could be affected by not taking the medicine;
- is directed solely or mainly at children;
- refers to a recommendation by scientists, healthcare professionals or celebrities;
- suggests that the medicinal product is a foodstuff, cosmetic or other consumer product;
- suggests that the therapeutic effect or safety of the medicinal product is based on its origins from nature;
- could easily lead to an incorrect self-diagnosis or self-cure due to a detailed representation of a case history;
- refers in inappropriate, intimidating or misleading terms to claims of recovery;

- uses inappropriate, intimidating or misleading terms, pictorial representations of changes caused in the human body by disease or injury, or of the effect of a medicinal product in the human body or its parts; or
- mentions that the medicinal product has been granted a marketing authorisation.

6.2 Is it possible to advertise prescription-only medicines to the general public? If so, what restrictions apply?

It is prohibited to market prescription-only medicines or medicines containing narcotics or psychotropic substances to the general public.

6.3 If it is not possible to advertise prescription-only medicines to the general public, are disease awareness campaigns permitted encouraging those with a particular medical condition to consult their doctor, but mentioning no medicines? What restrictions apply?

Disease awareness campaigns are allowed, provided they are not, even indirectly, intended to promote the sale of a medicine. Notwithstanding question 6.2 above, it is acceptable to provide information on prescription medicines to the general public, provided the information only contains essential information consistent with the summary of product characteristics or the package insert. The information given can also refer to prescription-only medicines if the information is of an impartial and factual nature, and covers all alternative medicines on the market. In such cases, sufficient information on non-medicinal forms of treatment must also be given. The PIF Code contains more detailed criteria for awareness campaigns, concerning e.g. the visual image of the awareness information and internet sites containing health awareness material.

6.4 Is it possible to issue press releases concerning prescription-only medicines to non-scientific journals? If so, what conditions apply? Is it possible for the press release to refer to developments in relation to as yet unauthorised medicines or unauthorised indications?

Please see questions 2.3 and 6.3 above and question 6.5 below. In case developments as to unauthorised medicines or unauthorised indications are referred to, the publication should not involve any elements of marketing whatsoever.

6.5 What restrictions apply to describing products and research initiatives as background information in corporate brochures/Annual Reports?

Information focusing primarily on the operations of the company, as well as corporate image marketing and business representation with no direct objective of promoting sales of medicines, are excluded from the scope of the PIF Code. In addition, press releases based on the information that a pharmaceutical company is obliged to provide, as well as informative notices (e.g. changes in packaging or warnings about adverse effects), are not considered promotional according to the Medicines Decree.

It should be noted, however, that the marketing provisions of the Medicines Act and Decree and the PIF Code apply to all forms of marketing and promotional activities by pharmaceutical companies,

and the context and subject matter are decisive in determining whether or not an activity amounts to the promotion of medicinal products. A non-promotional item may be used for a promotional purpose and therefore come within the scope of the relevant legislation and industry rules. Consequently, material issued by companies which relates to medicines, but which is not designed as promotion for those medicines, such as corporate information, press releases, financial information for shareholders and the Stock Exchange and responses to unsolicited enquiries from the public, should be examined to ensure that they do not contravene the Medicines Act or Decree or the PIF Code.

6.6 What, if any, rules apply to meetings with, and the funding of, patient organisations?

The PIF Code contains guidelines on cooperation with patient organisations. In the PIF Code it is also stated that the EFPIA Code should be applied. Providing support to patient groups is not prohibited as such. However, the (financial) support shall not be used to circumvent the legislation and PIF Code. Donations are only allowed if their purpose is to support healthcare and research, and if information regarding donations is properly documented and filed by the donator. Donations will not be accepted in cases where the nature of the cooperation may jeopardise the public trust in the impartiality of the prescription and supply of medicines. All donations and sponsorship, direct or indirect, should be disclosed by pharmaceutical companies to ensure transparency. It should also be noted that in the materials and publications created jointly by a patient organisation and the pharmaceutical company, the editorial material shall be based on editorial initiatives and assessments. The editorial and promotional material shall be clearly separated. Finally, when a pharmaceutical company sponsors e.g. a scientific event organised by the patient organisation, this should be clearly indicated in the invitations and programmes.

6.7 May companies provide items to or for the benefit of patients? If so, are there any restrictions in relation to the type of items or the circumstances in which they may be supplied?

As a general rule, restrictions on marketing to consumers apply to patients as well. Giveaways or medicinal product samples cannot be distributed to consumers in sales promotion. In addition, prize-winning competitions and lotteries are prohibited. Please also see questions 6.1 and 6.2 above.

Patient instructions must always be delivered by the company to physicians or other healthcare professionals, and they must not be generally available to consumers. When delivering the material, the recipient must be informed clearly that the patient instructions are merely intended for particular patients to support their treatment prescribed to them, and are not generally distributable to all patients.

7 Transparency and Disclosure

7.1 Is there an obligation for companies to disclose details of ongoing and/or completed clinical trials? If so, is this obligation set out in the legislation or in a self-regulatory code of practice? What information should be disclosed, and when and how?

There is no express obligation to disclose details of clinical trials in marketing.

However, the Medicines Decree stipulates that marketing material may not omit an essential detail, the omission of which could give a false impression. Further, according to the Medicines Decree, marketing may not refer to any clinical trial in a way that misrepresents the conclusions, extent or significance of the trial.

7.2 Is there a requirement in the legislation for companies to make publicly available information about transfers of value provided by them to healthcare professionals, healthcare organisations or patient organisations? If so, what companies are affected (i.e. do these requirements apply to companies that have not yet been granted a marketing authorisation and/or to foreign companies), what information should be disclosed, from what date and how?

Yes. The Medicines Act stipulates that the holder of a marketing authorisation or other entity marketing a medicine should make publicly available, e.g. at the company's webpage, an updated list of direct or indirect economic or other benefits which it has granted to medical or healthcare associations or patient organisations. The disclosure obligation concerns both national and foreign companies that are marketing their (authorised) products in Finland.

7.3 Is there a requirement in your self-regulatory code for companies to make publicly available information about transfers of value provided by them to healthcare professionals, healthcare organisations or patient organisations? If so, what companies are affected (i.e. do these requirements apply to companies that have not yet been granted a marketing authorisation and/or to foreign companies), what information should be disclosed, from what date and how? Are companies obliged to disclose via a central platform?

Yes. There is a requirement in the PIF Code for companies to make publicly available transfers of value annually provided by them to healthcare organisations and healthcare professionals who have their place of business in Europe. The disclosure obligation concerns both national and foreign member companies of PIF that are marketing their (authorised) products in Finland.

The member companies of PIF will be affected by the rules regarding the disclosure of transfers of value. The first reporting period for which these rules apply is the calendar year 2015. As a main rule, the economic liaisons are published by specifying the name of the recipient, while the values of the economic benefits received by the individual recipient are published for each reporting period by classifying them in certain stipulated categories, e.g. donations and grants, contributions to the costs of events and service and consultations fees. The economic benefits received by a recipient can be published by annual aggregate categories, provided that the individual sums can be presented at request.

The publication should be done in the Finnish language on the company's webpage, following PIF's template. The company must provide a brief presentation of the methods used in the publication and identification of each category. The publication takes place annually within six months from the end of each reporting period. The reporting period is one full calendar year. The data must be kept publicly accessible for at least three years, and stored for at least five years.

7.4 What should a company do if an individual healthcare professional who has received transfers of value from that company, refuses to agree to the disclosure of one or more of such transfers?

Due to data protection regulations, publication of data on individuals requires consent from the person in question. If such consent is not obtained, the data is disclosed without the name of the person involved. However, the associations of Finnish healthcare professionals generally support the disclosure.

8 The Internet

8.1 How is Internet advertising regulated? What rules apply? How successfully has this been controlled?

No, there are no legal or code requirements for companies to have specific standard operating procedures, although most companies have such in place.

Basically, the same rules apply to internet advertising as to advertising through other media. Marketing or advertising products which are to be sold by prescription, or which contain narcotics or psychotropic substances, are prohibited unless aimed at persons entitled to prescribe those medicines.

Based on our experience, the Finnish authorities react quite expediently to internet advertising, as they do not consider them to be fulfilling the legal requirements. The companies usually agree to change their advertising after having received a notice thereof.

8.2 What, if any, level of website security is required to ensure that members of the general public do not have access to sites intended for healthcare professionals?

According to the Medicines Act, electronic marketing to healthcare professionals shall be implemented in such a secure manner that it cannot target the general public. Thus, if the marketing or advertisement is carried out through electronic media, such as an extranet or another limited access system, the marketer must ensure that unauthorised persons cannot access it (e.g. passwords and registration requirements for physicians). A general warning such as "information for medical professionals only" is not sufficient.

8.3 What rules apply to the content of independent websites that may be accessed by a link from a company-sponsored site? What rules apply to the reverse linking of independent websites to a company's website? Will the company be held responsible for the content of the independent site in either case?

The content restrictions set by the Finnish regulations regarding the marketing of medicinal products also apply to websites accessed by links. According to the guidelines on the marketing of medicinal products on the internet produced by FIMEA, independent websites that may be accessed by links from a company website need to comply with the Finnish regulations even if the independent website is in another language than Finnish or Swedish. Consequently, it is prohibited to have a link to a website in which marketing

prescription-only medicinal products or products containing narcotics or psychotropic substances are marketed unless the site is only accessible to persons entitled to prescribe those medicinal products (see also question 7.2). There are no specific rules based on which the company would be held responsible for reverse linking.

The holder of the marketing authorisation is responsible for compliance with the Finnish legislation of an independent website which is accessible by link from the marketing authorisation holder's website.

8.4 What information may a pharmaceutical company place on its website that may be accessed by members of the public?

Marketing of prescription-only medicinal products or products containing narcotics or psychotropic substances to the general public is prohibited under the Medicines Act. However, a pharmaceutical company may publish the summary of the product characteristics or the package leaflet approved by an authority on the company's website, provided that the summary or the insert has not been amended or abridged.

It is deemed possible to publish user instructions of such medicinal products whose dosing requires particular knowledge or use of particular auxiliary means, e.g. user instructions for inhalers or insulin pens.

A pharmaceutical company may generally also briefly mention that a particular medicinal product or active ingredient is used for the treatment of a particular disease. Demonstration of, *inter alia*, indications, therapeutic statements, effects or other such features of the medicinal product may, however, be considered marketing or advertising, which is prohibited as regards to prescription-only medicinal products.

The acceptability of published information is considered on a case-by-case basis depending on the context of the information.

8.5 Are there specific rules, laws or guidance, controlling the use of social media by companies?

No specific regulation exists. The same rules basically apply to social media as to advertising through other media.

9 Developments in Pharmaceutical Advertising

9.1 What have been the significant developments in relation to the rules relating to pharmaceutical advertising in the last year?

Mobile applications are continuing to be used as a means of advertising, meaning that the obligation of companies to ensure compliance with the relevant regulation also when cooperating with third parties is accentuated.

9.2 Are any significant developments in the field of pharmaceutical advertising expected in the next year?

There are no expected significant developments in the next year.

9.3 Are there any general practice or enforcement trends that have become apparent in your jurisdiction over the last year or so?

There are no major changes in general practice or enforcement that have become apparent in 2017.

**Mikael Segercrantz**

Roschier, Attorneys Ltd.
Kasarmikatu 21 A
00130 Helsinki
Finland

Tel: +358 20 506 6000
Email: mikael.segercrantz@roschier.com
URL: www.roschier.com

Mikael Segercrantz is a Helsinki-based Partner in Roschier's Pharma & Life Sciences team. He advises on a wide variety of intellectual property, regulatory and advertising matters with emphasis on pharmaceuticals. Mikael is recognised as a leading expert in intellectual property and life sciences regulatory in Finland by international legal directories such as *Chambers Europe*, *Chambers Global*, *The Legal 500*, *IAM Patent 1000*, *MIP IP stars*, *Who's Who Legal* and *WTR 1000*. Clients admire not only his work, but also his personability, saying: "His legal work is excellent and he's really an expert in the field. He is also easy-going and responsive". (*Chambers Europe*, 2017). He is also described as an "enthusiastic, diligent lawyer with a focus on quality" (*WTR 1000*, 2015). He received his LL.M. from the University of Helsinki in 1997.

**Johanna Lilja**

Roschier, Attorneys Ltd.
Kasarmikatu 21 A
00130 Helsinki
Finland

Tel: +358 20 506 6000
Email: johanna.lilja@roschier.com
URL: www.roschier.com

Johanna Lilja is a Helsinki-based Partner in Roschier's Pharma & Life Sciences team. She regularly advises pharmaceutical companies in intellectual property (with particular focus on IP litigation and anti-counterfeiting enforcement), data privacy, marketing, regulatory and other compliance matters. She is recognised as a leading expert in Finland in the fields of intellectual property and life sciences by *Chambers Europe*, *Chambers Global*, *MIP IP stars* and *Who's Who Legal*, according to which Johanna is "a very talented young professional with a very pragmatic approach" (*Chambers Europe*, 2017). She also receives praise for her "super-smart, personable and professional manner" as well as her "innate understanding of the right path to take" (*Who's Who Legal*, 2017). Johanna was selected as a winner of the ILO Client Choice in 2017. She received her LL.M. from the University of Helsinki in 2004.

ROSCHIER

Roschier is one of the leading law firms in the Nordic region. The firm is well-known for its excellent track record of advising on demanding international business law assignments and large-scale transactions. Roschier's main offices are located in Helsinki and Stockholm.

The lawyers of Roschier's Pharma & Life Sciences team are experienced in serving and representing leading multinational and domestic companies in the pharmaceutical and biosciences industry. They advise companies in a wide range of matters including corporate, commercial, transactional, IP, product liability and regulatory services and have successfully handled a number of landmark pharmaceutical patent litigations and regulatory proceedings.

In addition to cutting-edge patent cases, the team handles the full range of regulatory, commercial and transactional advice for large pharmaceutical and medical device manufacturers.

Please visit www.roschier.com for more information.

Other titles in the ICLG series include:

- Alternative Investment Funds
- Anti-Money Laundering
- Aviation Law
- Business Crime
- Cartels & Leniency
- Class & Group Actions
- Competition Litigation
- Construction & Engineering Law
- Copyright
- Corporate Governance
- Corporate Immigration
- Corporate Investigations
- Corporate Recovery & Insolvency
- Corporate Tax
- Cybersecurity
- Data Protection
- Employment & Labour Law
- Enforcement of Foreign Judgments
- Environment & Climate Change Law
- Family Law
- Fintech
- Franchise
- Gambling
- Insurance & Reinsurance
- International Arbitration
- Investor-State Arbitration
- Lending & Secured Finance
- Litigation & Dispute Resolution
- Merger Control
- Mergers & Acquisitions
- Mining Law
- Oil & Gas Regulation
- Outsourcing
- Patents
- Private Client
- Private Equity
- Product Liability
- Project Finance
- Public Investment Funds
- Public Procurement
- Real Estate
- Securitisation
- Shipping Law
- Telecoms, Media & Internet
- Trade Marks
- Vertical Agreements and Dominant Firms



59 Tanner Street, London SE1 3PL, United Kingdom
Tel: +44 20 7367 0720 / Fax: +44 20 7407 5255
Email: info@glgroup.co.uk

www.iclg.com